To address the national shortage of academic gynecologic oncologists, the Department of Gynecologic Oncology at The University of M. D. Anderson Cancer Center has dedicated its T32 training program to producing outstanding academic Gynecologic Oncologists-both clinician investigators and physician-scientists. Our T32 trainees develop the research background skills necessary to be productive investigators. Moreover, we are committed to providing T32 training to groups that are underrepresented in academic gynecologic oncology, including minority individuals and women. Our program provides opportunities in a broad range of research training disciplines including, but not limited to, cancer biology, molecular therapeutics, tumor immunology, health disparities, epidemiology, and health services research. This 4-year program includes 24 months of research training followed by 24 months of clinical training. Two types of research training are offered: 1) a physician-scientist track in which trainees spend 24 months in the laboratory, and 2) a population-based research track in which trainees spend 24 months under the direction of one or two of the faculty mentors;the latter track may include one year of laboratory-based research followed by a year of population-based research or two years of population-based research. Additionally, during the research years, each fellow is required to complete a core of three courses and earn an advanced degree- either an M.S. degree or an M.P.H. degree-in the Graduate School of Biomedical Sciences or the UT School of Public Health, respectively. This versatility in academic training increases the likelihood of obtaining an academic position upon completion of training. The mentors in our program-physician-scientists and research scientists with active research programs supported by external peer-reviewed funding-are committed to a high quality research experience focused on gynecologic cancers. The University of Texas M. D. Anderson Cancer Center vigorously promulgates a core mission of excellence in research, education, and patient care. As a result, this is a highly stimulating environment in which aspiring academic gynecologic oncologists can receive research training under the aegis of the T32 program.

Public Health Relevance

This program is especially relevant to Public Health as it gives gynecologic oncology fellows the opportunity to train to become physician-scientists or population-based investigators. As the population ages and the number of oncologists declines, this program is critical to help meet future demands for oncology services and training the next generation of academic gynecologic oncologists.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA101642-09
Application #
8700128
Study Section
Subcommittee B - Comprehensiveness (NCI)
Program Officer
Lim, Susan E
Project Start
2003-07-01
Project End
2016-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
9
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Other Health Professions
Type
Hospitals
DUNS #
City
Houston
State
TX
Country
United States
Zip Code
77030
Kurnit, Katherine C; Dumbrava, Ecaterina E Ileana; Litzenburger, Beate et al. (2018) Precision Oncology Decision Support: Current Approaches and Strategies for the Future. Clin Cancer Res 24:2719-2731
Suidan, Rudy S; Sun, Charlotte C; Cantor, Scott B et al. (2018) Three Lymphadenectomy Strategies in Low-Risk Endometrial Carcinoma: A Cost-Effectiveness Analysis. Obstet Gynecol 132:52-58
Taylor, Jolyn S; He, Weiguo; Harrison, Ross et al. (2018) Disparities in treatment and survival among elderly ovarian cancer patients. Gynecol Oncol 151:269-274
Hillman, R Tyler; Chisholm, Gary B; Lu, Karen H et al. (2018) Genomic Rearrangement Signatures and Clinical Outcomes in High-Grade Serous Ovarian Cancer. J Natl Cancer Inst 110:
Jazaeri, Amir; Coleman, Robert L; Sood, Anil K et al. (2018) A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. Gynecol Oncol 151:374-380
Allen, Julie K; Armaiz-Pena, Guillermo N; Nagaraja, Archana S et al. (2018) Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. Cancer Res 78:3233-3242
Armbruster, Shannon D; Song, Jaejoon; Gatus, Leticia et al. (2018) Endometrial cancer survivors' sleep patterns before and after a physical activity intervention: A retrospective cohort analysis. Gynecol Oncol 149:133-139
Huang, Yan; Hu, Wei; Huang, Jie et al. (2018) Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. Mol Cancer Ther 17:464-473
Armbruster, Shannon D; Sun, Charlotte C; Westin, Shannon N et al. (2018) Prospective assessment of patient-reported outcomes in gynecologic cancer patients before and after pelvic exenteration. Gynecol Oncol 149:484-490
Hinchcliff, Emily; Hong, David; Le, Hung et al. (2018) Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials. Gynecol Oncol 151:407-413

Showing the most recent 10 out of 295 publications